Clinical trials: End of Life Patients
Refractory Epilepsy, Arrhythmia
Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death
People with epilepsy are at a higher risk for sudden unexpected death than the general population. Sudden unexpected death in epilepsy (SUDEP) is a major cause of death in this population, accounting for 10-50% of deaths for…
- Conditions
- Refractory Epilepsy, Arrhythmia, Sudden Death
- Trial name
- NCT00203333
- Testing
- Medtronic REVEAL
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Thomas Jefferson University
Recurrence, Metastasis
The Clinical Relevance of Immune Cells and CTC in HNSCC Patients
Head and neck squamous cell carcinomas (HNSCCs) are mainly caused by tobacco, alcohol consumption and betel nut chewing and the sixth most common cancer in the world.
- Conditions
- Recurrence, Metastasis, Death
- Trial name
- NCT02420600
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Critical Illness
Intensive Care Decision-making, Survival and Dying Well
The goal of this study is to investigate how the experiences of intensive care patients and their end-of-life wishes affect their willingness to accept intensive care treatment at different chances of survival.
- Trial name
- NCT06027684
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Large Cell Lung Cancer, Neuroendocrine Carcinoma of Lung (Diagnosis)
Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)
Observational, multicentre, retrospective study on patients taken care according to the national guidelines. The objective is to define, after the diagnosis confirmation, the frequency of PD-L1 expression in patients with…
- Trial name
- EPNEC (NCT03305133)
- Testing
- Immunohistochemistry
- Where
- 28 sites in France
- Volunteers
- 86 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Intervention Compliance, Usability
CSDM: A Trial to Improve Communication and Shared Decision Making Using a Web-Based Tool
The goal is to develop a pragmatic, scalable intervention to overcome problems with surrogate decision making in ICUs. The aim is to conduct a pilot study among surrogates and clinicians of 50 incapacitated patients at high risk…
- Conditions
- Intervention Compliance, Usability, Acceptability
- Trial name
- CSDM Pilot (NCT02955563)
- Testing
- CSDM Web-Based Tool Intervention
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Coronary Vasospasm, Cardiac Death
Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry
The purpose of this study is to evaluate the natural course of coronary spasm patients presenting aborted sudden cardiac death and analyze risk factors.
- Trial name
- NCT02298543
- Testing
- coronary spasm
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seung-Jung Park
Sudden Cardiac Death, End Stage Renal Disease
T-Wave Alternans in Dialysis Patients
Sudden cardiac death due to arrhythmia is the leading cause of death in end-stage renal disease (ESRD) patients treated with hemodialysis (HD).
- Trial name
- NCT00621426
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Gastric Neoplasms, Gastroesophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- Conditions
- Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- HERIZON-GEA-01 (NCT05152147)
- Testing
- Zanidatamab, Tislelizumab, Trastuzumab
- Where
- 227 sites in Argentina, Australia and 31 more
- Volunteers
- 920 people
- Sponsor
- Jazz Pharmaceuticals
Ventricular Tachycardia, Sudden Cardiac Death
Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker
The long-chain n-3 polyunsaturated fatty acids (PUFA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), appear to offer protection against sudden cardiac death and ventricular arrhythmias.
- Trial name
- NCT00534300
- Testing
- Omegaven, Isotonic saline
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- Aalborg University Hospital
Pulmonary Embolism, Lung Cancer
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the…
- Trial name
- NCT06017271
- Testing
- CTPA (computed tomography pulmonary angiography)
- Where
- China
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Atrial Fibrillation
COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation (COOL-AF) Phase 2
Atrial fibrillation (AF) is a leading cause of cardiovascular mortality and morbidity. Asian patients with AF have a higher rate of major bleeding including intracranial hemorrhage (ICH) compared to non-Asians.
- Trial name
- NCT06396299
- Testing
- No intervention
- Where
- 33 sites in Thailand
- Volunteers
- 4,000 people
- Sponsor
- Mahidol University
Refractory Pains, End of Life Patients
Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit
In the palliative care unit, certain patients suffer from pain associated with medical procedures/care which is poorly controlled by antalgics.
- Trial name
- PROPOPAL1 (NCT02198404)
- Testing
- sedation with propofol
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Leukemia, Promyelocytic, Acute
Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
Acute promyelocytic leukemia (APL) is a very rare type of leukemia. Because it is so rare, many doctors do not have experience treating it. APL has been shown to be curable most of the time.
- Trial name
- NCT02309333
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- Emory University
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or…
- Trial name
- KATE3 (NCT04740918)
- Testing
- Trastuzumab Emtansine, Atezolizumab
- Where
- 51 sites in United States, Australia and 17 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Biliary Tract Cancer
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with…
- Trial name
- FOENIX-BTC (NCT07710885)
- Testing
- Futibatinib, Zimberelimab, Durvalumab
- Where
- 21 sites in Australia, Japan and 2 more
- Volunteers
- 784 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Quality of Life
Comparison of Postoperative Early Period Quality of Life of Patients With Open and Robot Assisted Kidney Transplantation
The investigators aimed to investigate the quality of life in patients with end-stage renal disease who underwent open or robot-assisted renal transplantation.
- Trial name
- NCT04435171
- Testing
- Renal transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Heart Failure, Heart Failure With Reduced Ejection Fraction
CRTd Responders Optimization
Suboptimal optimization of atrio-ventricular (AV) and inter-ventricular (VV) timings could affect the clinical response of CRTd in T2DM patients.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiac Death
- Trial name
- NCT04547244
- Testing
- echocardiographic optimization of CRTd
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Campania Luigi Vanvitelli
Known CAD, or Intermediate-high Pretest Likelihood for CAD
Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)
Three main clinical outcomes will be assessed: 1. Post-test resource utilization as assessed by referral rate to catheterization within 90-days of the index study; 2.
- Trial name
- SPARC (NCT00321399)
- Where
- 41 sites in United States, Canada
- Volunteers
- 3,019 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure and Reduced Ejection Fraction
Developing a Digital Aid to Improve ICD Decisions
Advanced heart failure, affecting 7 million Americans, has multiple causes and results in greatly increased risk of disability and death.
- Trial name
- NCT07084142
- Testing
- Online, patient-facing decision-making aid (app) with personalized risk information., Implantable Cardioverter Defibrillator (ICD), Online, patient-facing decision-making app without personalized risk information.
- Where
- 2 sites in United States
- Volunteers
- 600 people
- Sponsor
- Stanford University
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs